Kovaltry (Octocog Alfa)

Octocog alfa is a bioengineered version of human factor VIII. It binds to von Willebrand factor in the bloodstream and restores the missing activity in the intrinsic coagulation pathway, allowing factor X to be activated to Xa, which then generates thrombin and forms a stable fibrin clot to stop bleeding.

The dose of Kovaltry is individualized. A qualified prescriber determines the amount based on the patient’s factor VIII activity level, body weight, severity of the bleed or surgical requirement, and clinical response. Dosing regimens are not standardized and should follow the prescribing information.

Safety data for Kovaltry in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainties with the patient and consider alternative management strategies when appropriate.

To order Kovaltry, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and reply with pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Kovaltry is a recombinant, third‑generation factor VIII concentrate with a high specific activity and a low risk of viral transmission. Compared with plasma‑derived products, it offers consistent purity and eliminates the need for viral inactivation steps. Relative to other recombinant products, Kovaltry’s pharmacokinetic profile may allow less frequent dosing for prophylaxis, but individual response varies.

Kovaltry must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Before reconstitution, inspect the vial for any particulates or discoloration. Once reconstituted, the solution should be used promptly according to the manufacturer’s instructions.

Kovaltry is supplied as a lyophilized powder that is reconstituted with a sterile diluent to form a solution for injection. The prepared solution is administered intravenously, typically through a peripheral or central line, under the supervision of a qualified healthcare professional. Administration technique follows standard intravenous infusion guidelines.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor VIII, which can render the product ineffective, and severe hypersensitivity reactions such as anaphylaxis. Thromboembolic events, although rare, may also occur, especially if factor levels become excessively high. Patients should be monitored closely for these events.

Kovaltry should not be used in individuals with a known hypersensitivity to octocog alfa, any of the excipients in the formulation, or other recombinant factor VIII products. Patients with a history of severe inhibitor development should be evaluated carefully, and alternative therapies may be considered. Use is also contraindicated in patients for whom intravenous administration is not feasible.